Price T Rowe Associates Inc Black Diamond Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 813,066 shares of BDTX stock, worth $3.85 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
813,066Holding current value
$3.85 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
100Shares Held
47.3MCall Options Held
108KPut Options Held
24.8K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$50.4 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$40.3 Million0.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$21 Million1.96% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$15.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.13MShares$10.1 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $172M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...